Apelin promotes RANKL‑mediated osteoclastogenesis by activating MAPK and NF‑κB pathways
Molecular Medicine Reports · 2025
DOI: 10.3892/mmr.2025.13751 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Medicine Reports, 2025. Verfasst von Yu-Han Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Medicine, China Medical University, Taichung 404328, Taiwan, R.O.C. Hauptthemen laut MEDLINE: RANK Ligand, Osteogenesis, Apelin, NF-kappa B. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The regulation of bone mass relies on a dynamic interplay between bone‑forming osteoblasts and bone‑resorbing osteoclasts. Imbalances in this regulatory system favor bone resorption and are implicated in the development of osteolytic disorders such as osteoporosis. Although current treatments targeting osteoclast activity are effective, safety concerns remain a notable limitation. As a multifunctional adipokine, apelin (APLN) serves a role in angiogenesis and metabolic regulation. However, to the best of our knowledge, its involvement in osteoclast differentiation has not yet been characterized. The present study thus examined the effects of APLN on osteoclastogenesis using a murine‑macrophage model stimulated with receptor activator of NF‑κB ligand (RANKL). The results revealed that APLN augmented RANKL‑induced osteoclast differentiation, promoting the formation of tartrate‑resistant acid phosphatase‑positive multinucleated cells and the development of organized F‑actin rings. Transcriptome analyses of a public dataset confirmed the temporal upregulation of osteoclast‑related genes under RANKL stimulation. It was further discovered that co‑treatment with APLN and RANKL significantly enhanced the expression of these osteoclast‑specific markers. APLN co‑treatment with RANKL upregulated the ERK, JNK, p38 and NF‑κB signaling pathways, and this activation was effectively attenuated by specific pathway inhibitors. In conclusion, these findings identified APLN as an enhancer of RANKL‑dependent osteoclast differentiation and signaling, suggesting that the modulation of APLN activity may provide a promising strategy for controlling excessive bone resorption in skeletal diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Medicine, China Medical University, Taichung 404328, Taiwan, R.O.C.
- Department of Orthopedics, Chung Shan Medical University Hospital, Taichung 402306, Taiwan, R.O.C.
- Department of Sports Medicine, College of Health Care, China Medical University, Taichung 402306, Taiwan, R.O.C.
- Department of Orthopedic Surgery, China Medical University Hospital, Taichung 404327, Taiwan, R.O.C.
Zitieren
APA
Wang, Y. H., Wu, Y. Y., Tsai, C. H., Fong, Y. C., Ko, C. Y., Chen, H. T., Law, Y. Y., & Tang, C. H. (2025). Apelin promotes RANKL‑mediated osteoclastogenesis by activating MAPK and NF‑κB pathways. Molecular Medicine Reports. https://doi.org/10.3892/mmr.2025.13751
Vancouver
Wang YH, Wu YY, Tsai CH, Fong YC, Ko CY, Chen HT, et al. Apelin promotes RANKL‑mediated osteoclastogenesis by activating MAPK and NF‑κB pathways. Molecular Medicine Reports. 2025. doi:10.3892/mmr.2025.13751
BibTeX
@article{Wang2025,
author = {Wang, Yu-Han and Wu, Yu-Ying and Tsai, Chun-Hao and Fong, Yi-Chin and Ko, Chih-Yuan and Chen, Hsien-Te and Law, Yat-Yin and Tang, Chih-Hsin},
title = {Apelin promotes RANKL‑mediated osteoclastogenesis by activating MAPK and NF‑κB pathways},
journal = {Molecular Medicine Reports},
year = {2025},
doi = {10.3892/mmr.2025.13751}
}
EUVIMED